UnitedHealthcare denies more genetic testing claims than any other major commercial payer. That's not opinion — it's the pattern you'll see if you're running a molecular lab and pulling your denial reports. The good news is that their requirements are published, their portals are functional, and their policies are consistent enough to work with once you understand them.
Disclaimer: This is educational, not billing, legal, or medical advice. Payer policies change frequently and your situation may differ from the examples here. Always verify current requirements with your payer's most recent published policy and consult qualified billing or compliance professionals. Use this information at your own risk.
UHC's Policy Structure Is Layered
UnitedHealthcare uses three tiers of policy documents, and your first job is knowing which one governs the service you're requesting.
Medical Policies are UHC's foundational coverage documents. For genetic testing, look for policies under their Genetic Testing section — there are separate policies for hereditary cancer panels, somatic tumor profiling, pharmacogenomics, and inherited cardiac conditions. These are publicly available at uhcprovider.com. They change on a rolling basis, typically with 90 days' notice, so a policy you reviewed 6 months ago may not be current.
Coverage Determination Guidelines (CDGs) are a second layer. CDGs often apply when a medical policy doesn't specifically address a test or when the plan is a self-insured employer plan with customized benefits. If you're getting a denial and the policy language doesn't seem to match, check whether a CDG is in play.
Prior Authorization Lists tell you whether a specific CPT or HCPCS code requires PA at all. UHC publishes these by plan type (commercial, Medicare Advantage, Medicaid). Don't assume that because a test requires PA for one employer group it requires PA for all — UHC's self-insured employer clients configure their own PA lists. Check Availity or the UHC Provider Portal before submitting.
The Right Portal Matters
For commercial UHC plans, PA requests go through Availity (availity.com) or through the UHC Provider Portal directly. Don't fax unless you've confirmed the plan requires it — fax submissions go into a queue that delays processing and makes follow-up harder.
For UHC Medicare Advantage plans, PA requests for certain high-cost genetic tests may route through eviCore. UHC has outsourced clinical review for some oncology testing categories to eviCore under their specialty benefit management arrangements. If you're requesting PA for an NGS panel under a UHC MA plan and you get routed to eviCore, don't fight it — log in to eviCore's portal (evicore.com) and follow their clinical pathway, which we cover in a separate article.
The UHC Provider Portal tracks PA status in real time. Use the reference number from your initial submission to follow up. If a request has been pending more than 3 business days without status update, call the UHC PA line — not your standard provider services line. The numbers differ, and provider services reps can't move PA requests.
What UHC's Genetic Testing Policies Actually Require
UHC's hereditary cancer panel policy covers multi-gene hereditary cancer panels (think BRCA1/2, Lynch syndrome, and expanded panels) when the patient meets defined personal or family history criteria. The policy lists specific risk criteria — a first-degree relative with a BRCA-positive result, prior cancer diagnosis at defined ages, Ashkenazi Jewish ancestry with qualifying family history. You need to document which criterion applies.
For somatic tumor profiling (comprehensive genomic profiling, NGS), UHC generally requires: confirmed solid tumor diagnosis, ICD-10 code for a specific cancer type, documentation of metastatic or locally advanced disease, and that the test is being ordered to guide treatment selection. Don't submit without specifying the cancer type in the diagnosis code — a generic "malignant neoplasm" code will get flagged.
Pharmacogenomics is a different story. UHC's coverage for PGx testing is narrow and highly code-specific. Many PGx CPT codes are excluded or covered only for specific drug-gene pairs with a limited list of indications. Before ordering, verify the specific CPT code against UHC's published coverage list.
UHC's Timelines and Your Appeal Rights
Standard PA decisions: UHC is required to respond within 15 calendar days for non-urgent requests, 3 business days for urgent/expedited, and 24 hours for life-threatening situations. These timelines apply to commercial and Medicare Advantage plans, though the regulatory basis differs.
If you get a medical necessity denial, you have the right to request a peer-to-peer review. Call the UHC PA line and ask specifically for a peer-to-peer; don't accept a callback from a nurse reviewer as a substitute. You want the ordering physician speaking with a UHC medical director who has authority to reverse the decision.
First-level appeals must be submitted within 180 days of the denial for most commercial plans. For Medicare Advantage, the redetermination window is typically 60 days. Missing these deadlines closes your appeal pathway, so calendar them immediately when a denial lands.
What Your Submission Needs to Include
- Member ID and plan name (confirm the plan type — commercial, MA, Medicaid)
- Ordering provider NPI and tax ID
- CPT or HCPCS code for the specific test or drug
- ICD-10 diagnosis codes — primary diagnosis first, then supporting codes
- Clinical notes that document the specific policy criteria the patient meets
- For hereditary cancer panels: family history documentation in the chart, not just referenced
- For somatic profiling: pathology report confirming tumor type and stage
UHC's denials for genetic testing are frequently overturned when the right documentation was simply not included in the initial submission. Check their published policy checklist before submitting, not after you get the denial.
Sources
- UHC Medical Policies — uhcprovider.com (current versions; verify before each submission)
- CMS-0057-F (2024 Interoperability and Prior Authorization Final Rule — PA response timelines for MA plans)
- 42 CFR §422.572–422.578 (Medicare Advantage coverage determination and appeals)
- 45 CFR §147.136 (internal claims and appeals — ACA-compliant commercial plans)
- CMS NCD 90.2 (next-generation sequencing in cancer — applicable to UHC MA plans)
- NCCN Clinical Practice Guidelines (NCCN.org) — referenced in UHC oncology policies